ES2534752T3 - Nuevo péptido antigénico contra el cáncer y utilización del mismo - Google Patents

Nuevo péptido antigénico contra el cáncer y utilización del mismo Download PDF

Info

Publication number
ES2534752T3
ES2534752T3 ES05814555.8T ES05814555T ES2534752T3 ES 2534752 T3 ES2534752 T3 ES 2534752T3 ES 05814555 T ES05814555 T ES 05814555T ES 2534752 T3 ES2534752 T3 ES 2534752T3
Authority
ES
Spain
Prior art keywords
peptide
sequence
antigenic peptide
against cancer
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05814555.8T
Other languages
English (en)
Inventor
Fumiyoshi Okano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Application granted granted Critical
Publication of ES2534752T3 publication Critical patent/ES2534752T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Péptido que comprende no menos de 7 aminoácidos consecutivos en la región de aa202-211 en la SEC ID NO: 2 en el LISTADO DE SECUENCIAS o péptido que comprende la misma secuencia de aminoácidos, a excepción de que uno o varios residuos de aminoácidos están sustituidos, eliminados y/o insertados y cuya secuencia tiene una identidad no inferior al 80% con el péptido que comprende no menos de 7 aminoácidos consecutivos en la región de aa202-211 en la SEC ID NO: 2 en el LISTADO DE SECUENCIAS o péptido que comprende de 8 a 31 residuos de aminoácidos que comprende cualquiera de dichos péptidos como secuencia parcial del mismo, para utilizar en un procedimiento para el tratamiento y/o la prevención de un cáncer o cánceres, en el que el péptido tiene una actividad inductora de la inmunidad.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10

Claims (1)

  1. imagen1
ES05814555.8T 2004-12-07 2005-12-06 Nuevo péptido antigénico contra el cáncer y utilización del mismo Expired - Lifetime ES2534752T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004353820 2004-12-07
JP2004353820 2004-12-07
PCT/JP2005/022369 WO2006062094A1 (ja) 2004-12-07 2005-12-06 新規癌抗原ペプチド及びその用途

Publications (1)

Publication Number Publication Date
ES2534752T3 true ES2534752T3 (es) 2015-04-27

Family

ID=36577921

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05814555.8T Expired - Lifetime ES2534752T3 (es) 2004-12-07 2005-12-06 Nuevo péptido antigénico contra el cáncer y utilización del mismo

Country Status (7)

Country Link
US (1) US7902143B2 (es)
EP (1) EP1835027B1 (es)
JP (1) JP5087925B2 (es)
CN (1) CN101072875B (es)
CA (1) CA2600898C (es)
ES (1) ES2534752T3 (es)
WO (1) WO2006062094A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
JP5151349B2 (ja) * 2006-09-26 2013-02-27 東レ株式会社 免疫誘導剤及びその用途
EP2245459A1 (en) 2008-01-23 2010-11-03 Herlev Hospital Ykl-40 as a general marker for non-specific disease
FR2932681B1 (fr) * 2008-06-20 2012-08-31 Commissariat Energie Atomique Peptides immunogenes issus de la proteine midkine comme vaccin anticancereux
AU2009291312A1 (en) 2008-09-15 2010-03-18 Herlev Hospital YKL-40 as a marker for gastrointestinal cancers
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
AU2016204712B2 (en) * 2008-10-01 2018-03-01 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including neuronal and brain tumors
WO2011027807A1 (ja) * 2009-09-03 2011-03-10 東レ株式会社 免疫誘導剤
WO2011036308A1 (en) * 2009-09-28 2011-03-31 Theramab Gmbh Method for preclinical testing of immunomodulatory drugs
WO2012027379A2 (en) * 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
WO2013173411A1 (en) 2012-05-16 2013-11-21 Stemline Therapeutics, Inc Cancer stem cell targeted cancer vaccines
CN106520800A (zh) * 2016-11-25 2017-03-22 南京医科大学第二附属医院 一种密码子优化的Chi3L1基因及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3023469B2 (ja) * 1992-02-21 2000-03-21 株式会社日本抗体研究所 糖タンパク質３９遺伝子
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US7229770B1 (en) * 1998-10-01 2007-06-12 The Regents Of The University Of California YKL-40 as a marker and prognostic indicator for cancers
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6881824B1 (en) * 1996-04-24 2005-04-19 Akzo Nobel N.V. Peptides suitable for use in antigen specific immunosuppressive therapy
TW575583B (en) * 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
US5726061A (en) * 1996-10-08 1998-03-10 Smithkline Beechum Corporation Method of diagnosing and monitoring colorectal cancer
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis

Also Published As

Publication number Publication date
CA2600898A1 (en) 2006-06-15
EP1835027A1 (en) 2007-09-19
US20090214480A1 (en) 2009-08-27
WO2006062094A1 (ja) 2006-06-15
EP1835027A4 (en) 2009-09-02
JP5087925B2 (ja) 2012-12-05
JPWO2006062094A1 (ja) 2008-06-12
CN101072875A (zh) 2007-11-14
CA2600898C (en) 2016-08-23
US7902143B2 (en) 2011-03-08
CN101072875B (zh) 2011-05-18
EP1835027B1 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
ES2652643T3 (es) Péptidos terapéuticos y su uso contra la corea de Huntington
AR122964A2 (es) Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
CL2019003405A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
ES2541217T3 (es) Diferenciación de células madre mesenquimales
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX392683B (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
PE20171111A1 (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso
AR083740A1 (es) Anticuerpos dkk1 (dickkopf-1) y metodos de uso
CO6190536A2 (es) Vacunas peptidicas para canceres que expresan antigenos asociados con tumores
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
CL2016001405A1 (es) A peptide mixture
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
CL2017003228A1 (es) Fragmentos mutantes de proteína ras
CY1119916T1 (el) Ανοσογονικη συνθεση
ES2524251T3 (es) Proteínas de tipo interferón humano recombinantes
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
AR085167A1 (es) Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit
CL2020003292A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)
GB201206070D0 (en) Clostridium difficile antigens
ES2544954T3 (es) Péptidos multiméricos ramificados para diagnóstico y terapia de tumores
CO2021017664A2 (es) Péptidos